MA45149A - Méthodes de traitement de la maladie d'alzheimer - Google Patents

Méthodes de traitement de la maladie d'alzheimer

Info

Publication number
MA45149A
MA45149A MA045149A MA45149A MA45149A MA 45149 A MA45149 A MA 45149A MA 045149 A MA045149 A MA 045149A MA 45149 A MA45149 A MA 45149A MA 45149 A MA45149 A MA 45149A
Authority
MA
Morocco
Prior art keywords
alzheimer
disease
treatment
methods
Prior art date
Application number
MA045149A
Other languages
English (en)
French (fr)
Inventor
Brendon Phillip Boot
Jeffrey Joseph Sevigny
Leslie Lugene Williams
Original Assignee
Biogen Int Neuroscience Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Int Neuroscience Gmbh filed Critical Biogen Int Neuroscience Gmbh
Publication of MA45149A publication Critical patent/MA45149A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
MA045149A 2016-06-07 2017-06-06 Méthodes de traitement de la maladie d'alzheimer MA45149A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662346818P 2016-06-07 2016-06-07
US201662435531P 2016-12-16 2016-12-16

Publications (1)

Publication Number Publication Date
MA45149A true MA45149A (fr) 2019-04-10

Family

ID=59067640

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045149A MA45149A (fr) 2016-06-07 2017-06-06 Méthodes de traitement de la maladie d'alzheimer

Country Status (12)

Country Link
US (2) US20200308259A1 (enExample)
EP (1) EP3464350A1 (enExample)
JP (3) JP2019517540A (enExample)
KR (2) KR20230165883A (enExample)
CN (3) CN114796481A (enExample)
AU (2) AU2017276656A1 (enExample)
BR (1) BR112018075300A2 (enExample)
CA (1) CA3026598A1 (enExample)
IL (1) IL263433B2 (enExample)
MA (1) MA45149A (enExample)
MX (1) MX2018015022A (enExample)
WO (1) WO2017211827A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201827467A (zh) 2016-11-03 2018-08-01 比利時商健生藥品公司 焦穀胺酸類澱粉蛋白－β之抗體及其用途
EP3696192A1 (en) 2019-02-15 2020-08-19 Consejo Superior De Investigaciones Científicas Therapeutic target and monoclonal antibodies against it for the diagnosis and treatment of alzheimer´s disease
US11236155B2 (en) 2019-03-26 2022-02-01 Janssen Pharmaceutica Nv Antibodies to pyroglutamate amyloid-β and uses thereof
CN110511276A (zh) * 2019-08-13 2019-11-29 王跃驹 植物作为宿主在表达Aducanumab抗体中的应用
WO2021081101A1 (en) * 2019-10-22 2021-04-29 Biogen Ma Inc. Anti-beta-amyloid antibody for treating alzheimer's disease
BR112023001061A2 (pt) 2020-07-23 2023-04-04 Othair Prothena Ltd Anticorpos antiabeta
KR102321601B1 (ko) * 2020-11-19 2021-11-05 주식회사 휴런 뇌 영상을 이용한 알츠하이머병의 생물학적 분류 장치 및 방법
WO2022261026A2 (en) * 2021-06-07 2022-12-15 Biogen Ma Inc. Methods for treating alzheimer's disease
US20250122146A1 (en) * 2021-09-30 2025-04-17 The Scripps Research Institute Compounds for reducing neuroinflammation
IL312715A (en) * 2021-11-19 2024-07-01 Ap Biosciences Inc Bispecific antibodies targeting cd137 and uses thereof for anti-cancer immunotherapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160049045A (ko) * 2006-07-14 2016-05-04 에이씨 이뮨 에스.에이. 아밀로이드 베타에 대해 인간화된 항체
CN101622275B (zh) 2007-01-05 2013-11-06 苏黎世大学 提供疾患特异性结合分子和靶的方法
CA2813493C (en) 2010-10-11 2019-07-09 University Of Zurich Human anti-tau antibodies
RU2651486C2 (ru) * 2012-10-15 2018-04-19 Медиммьюн Лимитед Антитела к бета-амилоиду
CA2894178A1 (en) * 2012-12-07 2014-06-12 Biogen International Neuroscience Gmbh A method of reducing brain amyloid plaques using anti-a.beta. antibodies
SG10201705104UA (en) 2012-12-21 2017-07-28 Biogen Int Neuroscience Gmbh Human anti-tau antibodies
BR112016018170A2 (pt) * 2014-02-08 2018-02-20 Genentech, Inc. métodos para tratar doença de alzheimer
MA41115A (fr) * 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer

Also Published As

Publication number Publication date
US20220281963A1 (en) 2022-09-08
JP2025160337A (ja) 2025-10-22
US20200308259A1 (en) 2020-10-01
EP3464350A1 (en) 2019-04-10
KR20230165883A (ko) 2023-12-05
AU2024216442A1 (en) 2024-10-17
WO2017211827A1 (en) 2017-12-14
JP2019517540A (ja) 2019-06-24
MX2018015022A (es) 2019-08-14
CN109476730A (zh) 2019-03-15
AU2017276656A1 (en) 2018-12-13
IL263433A (en) 2019-01-31
CN114796481A (zh) 2022-07-29
CA3026598A1 (en) 2017-12-14
IL263433B2 (en) 2024-03-01
CN114931635A (zh) 2022-08-23
IL263433B1 (en) 2023-11-01
KR20190021311A (ko) 2019-03-05
JP2022145965A (ja) 2022-10-04
BR112018075300A2 (pt) 2019-04-30

Similar Documents

Publication Publication Date Title
EP3645121A4 (en) METHOD OF TREATMENT FOR HUNTINGTON'S MORBUS
MA45149A (fr) Méthodes de traitement de la maladie d'alzheimer
EP3515505A4 (en) AAV TREATMENT BY MORBUS ALZHEIMER
EP3291815A4 (en) METHOD FOR TREATING A NEURODEEGENERATIVE DISEASE
MA41115A (fr) Procédé de traitement de la maladie d'alzheimer
EP3490582A4 (en) METHOD AND COMPOSITIONS FOR TREATING MYELOFIBROSE
EP3813808A4 (en) Methods of treating substance abuse
EP3644996A4 (en) METHOD OF TREATMENT FOR HUNTINGTON'S MORBUS
EP3528852A4 (en) METHOD AND COMPOSITIONS FOR TREATING MORBUS FABRY
EP3294345A4 (en) TPP1 FORMULATIONS AND METHOD FOR THE TREATMENT OF CLN2 DISEASES
EP3019523A4 (en) METHOD FOR THE TREATMENT OF MORBUS ALZHEIMER AND MORBUS HUNTINGTON
EP3452166A4 (en) INTRANASAL STIMULATION FOR THE TREATMENT OF DISEASES OF MEIBOM'S GLANDS AND BLEPHARITIS
EP3377118A4 (en) METHOD FOR THE TREATMENT OF MORBUS ALZHEIMER AND RELATED DISEASES
EP3402533A4 (en) METHOD AND COMPOSITIONS FOR TREATING NEUROLOGICAL DISEASE
MA53329A (fr) Méthodes de traitement de l'épilepsie
EP2978446A4 (en) METHOD AND MEANS FOR THE TREATMENT OF MORBUS ALZHEIMER
HUE059387T2 (hu) Parkinson-kór kezelése
PL3347002T3 (pl) Leczenie choroby alzheimera w konkretnej populacji pacjentów
EP3386520A4 (en) METHOD FOR THE TREATMENT OF EYE DISEASES OR DISORDERS
EP3393468A4 (en) METHOD FOR TREATING AN IMMUNE WEAKNESS
EP3454793A4 (en) TREATMENT COILS FOR ANEURYSMS
MA46353A (fr) Méthodes de traitement de l'infertilité féminine
EP3634422A4 (en) Methods of treating leukodystrophies
MA47395A (fr) Méthode pour le traitement d'une maladie neurologique
EP3546449A4 (en) PIPERIDINE-2,6-DIKETONE DERIVATIVE AND TREATMENT OF MORBUS CROHN